SARS–CoV-2–specific T cell responses and correlations with COVID-19 patient predisposition
Open accessThe DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). So far, viral targets of cellular immunity and factors determining successful mounting of T cell responses are poorly defined. We therefore analyzed cellular responses to membrane, nucleocapsid, and spike proteins in individuals suffering from moderate or severe infection and in individuals who recovered from mild disease. We demonstrate that the CoV-2-specific CD4+ T helper cell response is directed against all 3 proteins with comparable magnitude, ex vivo proliferation, and portions of responding patients. However, individuals who died were more likely to have not mounted a cellular response to the proteins. Higher patient age and comorbidity index correlated with increased frequencies of CoV-2-specific CD4+ T cells, harboring higher portions of IL-2-secreting, but lower portions of IFN-γ-secreting, cells. Diminished frequencies of membrane protein-reactive IFN-γ+ T cells were particularly associated with higher acute physiology and chronic health evaluation II scores in patients admitted to intensive care. CoV-2-specific T cells exhibited elevated PD-1 expression in patients with active disease as compared with those individuals who recovered from previous mild disease. In summary, our data suggest a link between individual patient predisposition with respect to age and comorbidity and impairment of CoV-2-specific Th1-type cellular immunity, thereby supporting a concept of altered T cell function in at-risk patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“suggesting a link between individual patient predisposition with respect to age and comorbidity [127, 128].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263 · cited 1×
“Interestingly, both risk factors overlap with those identified to generally predict mortality in a recent retrospective study (22).”
BackgroundAPACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Le Gall, J.-R. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.270.24.2957 · Cited by 7,773
APACHE II: a severity of disease classification system.
Knaus, W. A., Draper, E. S., Wagner, D. P., & Zimmerman, J. E. (1985) · PubMed · Cited by 6,034
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750 · cited 1×
“Consequently, 2 recent reports verified that patients with COVID-19 exhibit a trend toward lower frequencies IFN-γ+ cells after unspecific stimulation (20, 21), an observation that could be confirmed by using the polyclonal stimulus SEB.”
ResultA Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia
Fine, M. J., Auble, T. E., Yealy, D. M., Hanusa, B. H., Weissfeld, L. A., Singer, D. E., Coley, C. M., Marrie, T. J., & Kapoor, W. N. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701233360402 · Cited by 4,582
Cited by
Items 101–196 of 196
Riou, C., Schäfer, G., Bruyn, E. D., Goliath, R. T., Stek, C. J., Mou, H., Hung, D., Wilkinson, K. A., & Wilkinson, R. J. (2021) · European Respiratory Journal · doi:10.1183/13993003.00285-2021 · Cited by 17
“These observations are in accordance with other studies pointing out an impairment of SARS-CoV-2 adaptive immune responses characterised by low levels of type I and type II IFN [30, 31].”
Impaired SARS-CoV-2 specific T-cell response in patients with severe COVID-19
Rümke, L. W., Smit, W. L., Bossink, A. W. J., Limonard, G. J. M., Muilwijk, D., Haas, L. E. M., Reusken, C. B. E. M., van der Wal, S., Thio, B. J., van Os, Y. M. G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1046639 · Cited by 14
Where do T cell subsets stand in SARS-CoV-2 infection: an update
Tarique, M., Suhail, M., Naz, H., Muhammad, N., Tabrez, S. S. M., Zughaibi, T. A., Abuzenadah, A. M., Hashem, A. M., Shankar, H., Saini, C., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.964265 · Cited by 17
Novel coronavirus mutations: Vaccine development and challenges
Luo, W.-R., Wu, X., Wang, W., Yu, J., Chen, Q., Zhou, X., Huang, X., Pan, H., Liu, Z., Gao, Y., et al. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105828 · Cited by 19
Dolff, S., Zhou, B., Korth, J., Luo, D., Dai, Y., Jahn, M., Dorsch, O., Anastasiou, O. E., Witzke, O., Kribben, A., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.013 · Cited by 15
Tuberculosis and COVID-19 Dually Affect Human Th17 Cell Immune Response
Starshinova, A. A., Kudryavtsev, I. V., Rubinstein, A., Malkova, A. M., Dovgaluk, I., & Kudlay, D. A. (2023) · Biomedicines · doi:10.3390/biomedicines11082123 · Cited by 18
Táborská, P., Lašťovička, J., Stakheev, D., Strizova, Z. O., Bartůňková, J., & Smrž, D. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.496 · Cited by 17
Atanackovic, D., Kreitman, R. J., Cohen, J. I., Hardy, N. M., Omili, D. O., Iraguha, T., Burbelo, P. D., Gebru, E., Fan, X., Baddley, J. W., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004953 · Cited by 12
Platelets modulate CD4+ T‐cell function in COVID‐19 through a PD‐L1 dependent mechanism
Paletta, A. L., García, F. D. D., Varese, A., Díaz, F. A. E., García, J. L., Cisneros, J. C., Ludueña, G., Mazzitelli, I. G., Pisarevsky, A. A., Cabrerizo, G., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18062 · Cited by 17
Heinzel, A., Schrezenmeier, E. V., Regele, F., Hu, K., Raab, L., Eder, M., Aigner, C., Jabbour, R., Aschauer, C., Stefanski, A., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.936126 · Cited by 15
“The Tcell stimulation flow cytometric (FC) assessment of SARS-CoV2-specific T-cells has been described before (10, 11).”
MethodSalomé, B., & Horowitz, A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0613 · Cited by 13
“In fact, PD-1 expression has recently been shown to increase on SARS-CoV-2–specific CD4 T cells during acute infection and followed by a decrease in expression upon convalescence (2).”
BackgroundAgallou, M., Koutsoni, O. S., Michail, M., Zisimopoulou, P., Tsitsilonis, O., & Karagouni, E. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac421 · Cited by 13
“Memory B-cell activation and eventual antibody production are supported by the presence of antigen-specific cell responses, which are not necessarily dependent on follicular T cells [30, 31].”
BackgroundKonik, M., Lindemann, M., Zettler, M., Meller, L., Dolff, S., Rebmann, V., Horn, P. A., Dittmer, U., Krawczyk, A., Schipper, L., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194606 · Cited by 13
“In addition, all patients in this study survived their SARS-CoV-2 infection and thus were more likely to develop virus-specific immunity than patients who died as consequence of infection [37].”
BackgroundResultDoes dehydroepiandrosterone sulfate have a role in COVID-19 prognosis and treatment?
Tomo, S., Banerjee, M., Sharma, P., & Garg, M. K. (2021) · Endocrine Regulations · doi:10.2478/enr-2021-0019 · Cited by 12
Sarcoidosis-related autoimmune inflammation in COVID-19 convalescent patients
Rubinstein, A., Kudryavtsev, I. V., Malkova, A. M., Mammedova, J. T., Isakov, D., Isakova–Sivak, I., Kudlay, D. A., & Starshinova, A. A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1271198 · Cited by 11
Adaptive immune responses to SARS-CoV-2
Forthal, D. N. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.009 · Cited by 13
“ble magnitude, proliferation and proportion of responding patients, although anti-N cells were less likely to produce IFN-c, IFN-b and TNF-a [25].”
Chiu, C.-H., Chang, Y.-H., Chang, F., Hung, Y., Liao, C., Chiu, K., Tsai, P.-L., Chang, T.-W., & Yen, L.-C. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.862656 · Cited by 14
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIVPreprint
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-309746/v1 · Cited by 17
Are T cells helpful for COVID-19: the relationship between response and risk
Griffin, D. E. (2020) · Journal of Clinical Investigation · doi:10.1172/jci142081 · Cited by 10
Jotschke, S., Schulze, S., Jaekel, N., Ludwig‐Kraus, B., Engelmann, R., Kraus, F. B., Zahn, C., Nedlitz, N., Prange‐Krex, G., Mohm, J., et al. (2022) · Cancers · doi:10.3390/cancers14061544 · Cited by 10
“These T-cell responses were shown to be associated with improved survival after infections even in patients with hematologic neoplasms [35,36].”
BackgroundDifferential Cytokine Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir
Chan, Y., Young, B. E., Fong, S., Ding, Y., Goh, Y. S., Chee, R. S., Tan, S. Y., Kalimuddin, S., Tambyah, P. A., Leo, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680188 · Cited by 11
“-Duration (days, range) - 6 (5-27) - 8 (2-30)”
Sun, Z., Zhang, Z., Banu, K., Azzi, Y. A., Reghuvaran, A. C., Fredericks, S., Planoutene, M., Hartzell, S., Kim, Y., Pell, J. F., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2022010125 · Cited by 11
André, S., Azarias-da-Silva, M., Picard, M., Alleaume‐Butaux, A., Kundura, L., Cezar, R., Soudaramourty, C., Cruz, A. S., Mendes‐Frias, A., Carvalho, A., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05190-0 · Cited by 13
SARS-CoV-2 mRNA vaccination–induced immunological memory in human nonlymphoid and lymphoid tissues
Proß, V., Sattler, A., Lukassen, S., Toth, L., Thole, L. M. L., Siegle, J., Stahl, C., He, A., Damm, G., Seehofer, D., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci171797 · Cited by 11
“Along with their CD4 + counterparts, antigen-specific CD8 + T cells were identified within the same samples according to CD137 and IFN-γ coexpression, as recently shown (4, 16) with the gating strategy depicted in Supplemental Figure 1.”
Self-citationLuo, W., Gan, J., Luo, Z., Li, S., Wang, Z., Wu, J., Zhang, H., Xian, J., Cheng, R., Tang, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01751-1 · Cited by 9
“30,31 Hence, this study suggests that activation of Th1 cells plays a crucial role in response to declining antibody levels and emerging SARS-CoV-2 VOCs.”
BackgroundPickering, H. C., Schaenman, J. M. D., Phan, H. V., Maguire, C. P., Tsitsiklis, A., Rouphael, N., Higuita, N. I. A., Atkinson, M. A., Brakenridge, S. C., Fung, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55823-z · Cited by 8
Broad-spectrum coronavirus vaccines: integrated strategies to combat viral diversity
He, Q., Zhang, Y., Fu, Z., Ma, X., & Liang, Z. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2538561 · Cited by 8
T helper cell subsets and related target cells in acute COVID-19
Kudryavtsev, I. V., Головкин, А. С., & Тотолян, А. А. (2022) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-thc-1882 · Cited by 8
Akhtar, M., Basher, S. R., Nizam, N. N., Kamruzzaman, M., Khaton, F., Banna, H. A., Kaisar, M. H., Karmakar, P. C., Hakim, A., Akter, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1052374 · Cited by 12
“There is evidence that the type of helper T cells impacts the disease outcome of infection, including during SARS-CoV-2 infection, by the expression of activation or exhaustion markers (18, 41, 42).”
BackgroundMahalingam, S. S., Jayaraman, S., Arunkumar, A., Dudley, H. M., Anthony, D. D., Shive, C. L., Jacobson, J. M., & Pandiyan, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1231087 · Cited by 8
García‐Pérez, J., González-Pérez, M., de la Osa, M. C., Borobia, A. M., Castaño, L. A., Bertran, M. J., Campins, M., Portolés, A., Lora, D., Bermejo, M., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101529 · Cited by 7
Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients
Anft, M., Blazquez‐Navarro, A., Stervbo, U., Skrzypczyk, S., Witzke, O., Wirth, R., Choi, M., Hugo, C., Reinke, P., Meister, T. L., et al. (2021) · Journal of Nephrology · doi:10.1007/s40620-021-01092-0 · Cited by 8
Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population
Biswas, A., Mandal, R. S., Chakraborty, S., & Maiti, G. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1925267 · Cited by 8
Tegeler, C. M., Bilich, T., Maringer, Y., Salih, H. R., Walz, J. S., Nelde, A., & Heitmann, J. S. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.04.019 · Cited by 11
Multiscale PHATE Exploration of SARS-CoV-2 Data Reveals Multimodal Signatures of DiseasePreprint
Kuchroo, M. R., Huang, J., Wong, P., Grenier, J., Shung, D. L., Tong, A., Lucas, C. G. D. O., Klein, J., Burkhardt, D. B., Gigante, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.15.383661 · Cited by 11
“Multiple recent publications have addressed the question of protection conferred by T cell-mediated responses [77–79] - with many demonstrating that antigenspecificity and T cell responsiveness lead to improved outcomes [80, 81].”
BackgroundSattler, A., Gamradt, S., Pross, V., Thole, L., He, A., Schrezenmeier, E., Jechow, K., Gold, S. M., Lukassen, S., Conrad, C., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.166833 · Cited by 6
“In that respect, we previously showed that advanced age or increased comorbidity index shape the specific Th cell response toward reduced IFN-γ production in SARS-CoV-2–infected patients (6), a feature that was recapitulated in aged SARS-CoV-2 mRNA vac-cinees (22).”
InfluentialSelf-citationThe Role of Immune Regulatory Molecules in COVID-19
Khalifehzadeh-Esfahani, Z., Fattahi, S., Haratemeh, Z. H., & Jafarinia, M. (2022) · Viral Immunology · doi:10.1089/vim.2021.0211 · Cited by 6
“Sattler et al. demonstrated that the expression of PD-1 on CD4 + T cells, which increased in the acute phase, decreased during recovery (29).”
Altered pre-existing SARS-CoV-2-specific T cell responses in elderly individuals
Taira, N., Toguchi, S., Miyagi, M., Mori, T., Tomori, H., Oshiro, K., Tamai, O., Kina, M., Miyagi, M., Tamaki, K., et al. (2021) · Clinical Immunology Communications · doi:10.1016/j.clicom.2021.12.001 · Cited by 7
Schnizer, C., Andreas, N., Vivas, W., Kamradt, T., Baier, M., Kiehntopf, M., Glöckner, S., Scherag, A., Löffler, B., Kolanos, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1095129 · Cited by 8
“Furthermore, COVID-19 severity was associated with a stronger inflammatory T cell–mediated cytokine response against S, M, or N proteins early after infection (20, 21).”
Lesteberg, K. E., Araya, P., Waugh, K. A., Chauhan, L., Espinosa, J. M., & Beckham, J. D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113932 · Cited by 7
“Age (Median, range) 54 (25-87) 58 (26-91) 0.”
BackgroundResultUlakcsai, Z., Szabó, L. E., Szabo, Z., Karászi, É., Szabó, T. G., Fazekas, L., Vereb, A., Kovacs, N. F., Németh, D., Kovács, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1179620 · Cited by 7
Fan, X., Song, J., Cao, W., Zhou, M., Yang, T., Wang, J., Meng, F.-P., Shi, M., Zhang, C., & Wang, F. (2024) · Viruses · doi:10.3390/v16071006 · Cited by 6
“…that the dysregulation of Tumor Necrosis Factor-α /Tumor Necrosis Factor Receptor 1 signaling, upregulation of inhibitory receptors, and prolonged antigen exposure may contribute to the dysfunction observed in antigen-specific T-cell responses in COVID-19 patients with severe disease [35,37,38].”
BackgroundHarbour, J. C., Lyski, Z. L., Schell, J. B., Thomas, A., Messer, W. B., Slifka, M. K., & Nolz, J. C. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100054 · Cited by 6
A Virus-Specific Immune Rheostat in the Immunome of Patients Recovering From Mild COVID-19
Yeo, J. G., Leong, J. Y., Tay, S. H., Nadua, K. D., Anderson, D. E., Lim, A. J. M., Ng, X. W., Poh, S. L., Guo, D., Yaung, K. N., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674279 · Cited by 7
The Journal of Clinical Investigation in the time of COVID-19
Casadevall, A., Jackson, S., Semenza, G. L., Tomaselli, G. F., & Ahima, R. S. (2021) · Journal of Clinical Investigation · doi:10.1172/jci156409 · Cited by 6
Huang, Z., Sun, Q., Shi, H., Yang, S., Li, Y., Ma, Y., Yang, F., Shi, Z., Yang, Y., Zhang, Y., et al. (2023) · ChemPhysMater · doi:10.1016/j.chphma.2023.03.005 · Cited by 5
“A low number of CD4 lymphocytes would lead to a more severe case of SARS-CoV-2 infection [19, 20] .”
Backgroundvan Baal, L., Reinold, J., Benson, S., Diehl, A., Witzke, O., Führer-Sakel, D., & Tan, S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac590 · Cited by 7
“Patients with PreD/D showed lower CD8 count and higher CD4/CD8 ratio in line with a study by Sattler reporting an increased CD4/CD8 ratio in patients with COVID-19 and a comorbidity such as diabetes (30).”
ResultCOVID-19 and immunity: quo vadis?
Miyasaka, M. (2021) · International Immunology · doi:10.1093/intimm/dxab008 · Cited by 6
“Multiple distinct T cell response patterns have been reported in different patients, possibly as a result of the individuals’ co-morbidities, genetic burden, immunological state at the time of infection and other variables [39, 40].”
BackgroundGoliwas, K. F., Wood, A. M., Simmons, C. S., Khan, R., Khan, S. A., Wang, Y., Berry, J. L., Athar, M., Mobley, J. A., Kim, Y., et al. (2021) · medRxiv · doi:10.1101/2021.09.02.21263042 · Cited by 6
Ponce, L. J., Wang, Y., Singh, A., Chua, H. C., Chen, M., Hor, P. X., Loh, C. Y., Poh, X. Y., Rao, S., Chia, P. Y., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70521 · Cited by 5
Effects of nutrients on immunomodulation in patients with severe COVID-19: Current knowledge
da Costa, B. T., Araújo, G. R. L., Júnior, R. T. D. S., Santos, L. K. D. S., Gonçalves, V. L. D. S., Lima, D. B. A., Cuzzuol, B. R., Apolonio, J. S., de Carvalho, L. S., Marques, H. S., et al. (2022) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v11.i4.201 · Cited by 6
Lu, T., Man, Q., Yu, X., Xia, S., Lu, L., Jiang, S., & Xiong, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1157892 · Cited by 4
“Its expression level was elevated after SARS-CoV-2 infection and associated with disease severity (37, 38).”
BackgroundBuscot, M., Crémoni, M., Graça, D., Brglez, V., Courjon, J., Allouche, J., Teisseyre, M., Boyer, L., Barrière, J., Chamorey, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1145652 · Cited by 5
“Nonspecific cellular response (IFN-g, IU/mL) 84 [17-349] 9 [4-57] 123 [24-407] 0.”
Donadeu, L., Gómez‐Ollés, S., Casanova‐Ferrer, F., Torija, A., López‐Meseguer, M., Boada-Pérez, M., Kervella, D., Crespo, E., Carrera, C., Campos‐Varela, I., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1463769 · Cited by 6
Machine learning analysis of humoral and cellular responses to SARS-CoV-2 infection in young adults
Marcinkevičs, R., Silva, P. N., Hankele, A., Dörnte, C., Kadelka, S., Csik, K., Godbersen, S., Goga, A., Hasenöhrl, L., Hirschi, P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1158905 · Cited by 4
“While a CD8 T cell response is more prominent in mild courses, a CD4 T cell response is dominant in more severe disease courses, as previously reported (32, 33).”
ResultAzgomi, M. S., Manna, M. P. L., Badami, G. D., Ragonese, P., Trizzino, A., Dieli, F., & Caccamo, N. (2021) · Biomedicines · doi:10.3390/biomedicines9111576 · Cited by 4
Benefits of Ginger as Medicine for COVID-19: Literature Study
Utami, A. T., & Qarrah, A. G. A. (2022) · Journal of Biomedical Research & Environmental Sciences · doi:10.37871/jbres1580 · Cited by 6
“Older age and a higher rate of comorbidity were also associated with a lower number of IFN-γ-producing cells [187].”
BackgroundLong-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV
Augello, M., Bono, V., Rovito, R., Tavelli, A., Santoro, A., Tincati, C., Vergori, A., Azzini, A. M., Righi, E., Spiteri, G., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00799-6 · Cited by 4
Etemadi, J., Motavalli, R., Mirghaffari, A., Soltani‐Zangbar, M. S., Hajivalili, M., Heris, J. A., Niknafs, B., Vahed, S. Z., Sadeghi, M., Hashemi, S. R., et al. (2023) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24863 · Cited by 2
Stefanski, A., Rincón-Arévalo, H., Schrezenmeier, E. V., Karberg, K., Szelinski, F., Ritter, J., Chen, Y., Meisel, C., Jahrsdörfer, B., Ludwig, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943476 · Cited by 5
“As previously described, antigen-reactive CD4+ T cells were identified based on co-expression of CD154 and CD137, and antigen-reactive CD8+ T cells by co-expression of CD137 and IFNg ( (15, 19), gating strategy Supplementary Figures 3A, B).”
BackgroundDurability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days
Haymond, A. N., Damluji, A. A., Narayanan, A., Mueller, C., Reeder, A., Alem, F., Maxwell, G. L., Petricoin, E. F., Liotta, L. A., & deFilippi, C. R. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab140 · Cited by 3
“While correlates of protection in COVID19 are as yet unknown, including how cellular responses may provide protection apart from, or in conjunction with, antibody responses [6, 7], the prophylactic protection provided by administered neutralizing antibodies supports the hypothesis that neutralizing antibodies can prev…”
BackgroundActions and attitudes on the immunized patients against SARS-CoV-2
Ramos, P. D. L., Botella, A. G., García‐Lledó, A., Gómez‐Pavón, J., del Castillo, J. M. G., Hernández‐Sampelayo, T., Delgado, M. C. M., Martín‐Sánchez, F. J., Martínez‐Sellés, M., Molero, J., et al. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/131.2021 · Cited by 3
Cheng, Z., Liu, C., Lin, J., Lunbiao, C., Li, C., Guoxin, S., Xu, R., Xiangnan, G., Changxing, L., Chen, Y., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.16.444324 · Cited by 3
“stimulation factors, etc) and correlated receptors and proteins, might play important roles in the development of severe disease ([9-11]).”
BackgroundCoulon, P.-G. A., Prakash, S., Dhanushkodi, N. R., Srivastava, R., Zayou, L., Tifrea, D. F., Edwards, R. A., Cesar, J. F., Schubl, S. D., Hsieh, L. L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.30.478343 · Cited by 5
Lung-resident SARS-CoV-2 peptide-specific immune responses in perfused 3D human lung explant models
Goliwas, K. F., Wood, A. M., Simmons, C. S., Khan, R., Khan, S. A., Wang, Y., Ramachandran, R., Berry, J. L., Athar, M., Mobley, J. A., et al. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1587080 · Cited by 2
Wen, R., Li, J., Chen, F., Liu, J., Xu, P., Li, M., Liu, C., Tan, L., & Liu, C. (2024) · Hypertension Research · doi:10.1038/s41440-024-01953-8 · Cited by 2
“This leads to the proliferation and differentiation of T cells into Th1 cells, which secrete pro-in fl ammatory cytokines and ultimately trigger cytokine storms [26].”
Plasencia‐Rodríguez, C., Martínez‐Feito, A., Hernández-Díaz, M., Molina, L. D. P., Novella-Navarro, M., Serrano, Y., González‐Muñoz, M., Peiteado, D., Bonilla, G., Monjo, I., et al. (2023) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-023-00832-0 · Cited by 3
The role of T cell immunity in COVID-19
Stervbo, U., & Babel, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18566-3.00021-9 · Cited by 1
Daenen, K., van Hooijdonk, S., Tong‐Minh, K., Dik, W. A., van Hagen, P. M., Huijben, J. A., Gommers, D. A. M. P. J., Gorp, E. C. M. V., Endeman, H., & Dalm, V. A. S. H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1436637 · Cited by 1
Šlisere, B., Kārkliņš, R., Rivkina, A., Lejniece, S., & Oļeiņika, K. (2025) · Pathogens · doi:10.3390/pathogens14090890 · Cited by 2
“Lack of T cell responsiveness may be clinically important: impaired CD4 + T cell responses are linked to higher COVID-19 mortality [37], whereas preserved CD8 + T cells correlate with better outcomes even when antibodies are reduced [33].”
Caicedo, M. S., Flores, V., Siapno, R., Crosby, M., Samelko, L., Jacobs, J. J., & Hallab, N. J. (2023) · Journal of Orthopaedics · doi:10.1016/j.jor.2023.11.041 · Cited by 1
Соколенко, М. О., Соколенко, А., & Sokolenko, L. (2024) · Medical Science of Ukraine (MSU) · doi:10.32345/2664-4738.2.2024.06 · Cited by 1
Daungsupawong, H., & Wiwanitkit, V. (2025) · Clinical Transplantation · doi:10.1111/ctr.70249 · Cited by 1
“Recent studies have shown that memory B-cell responses can persist even after humoral antibody decline, indicating their potential role in durable immunity in immunocompromised individuals [2, 3].”
Bubba, L., Simmonds, P., Fischer, T. K., Harvala, H., Weseslindtner, L., Spuchhammer-Stockl, E., Marijke, R., Dedeić-Ljubović, A., Aleksandrova, D., Tabain, I., et al. (2021) · Journal of Global Health · doi:10.7189/jogh.11.05014 · Cited by 1
Caicedo, M. S., Flores, V., Padilla, A., Samelko, L., Jacobs, J. J., & Hallab, N. J. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02563-7
Santer, D. M., Li, D., Ghosheh, Y., Zahoor, M. A., Prajapati, D., Tyrrell, D. L., Feld, J. J., & Gehring, A. J. (2022) · medRxiv · doi:10.1101/2022.02.24.22271438
Alcamí, J., García‐Pérez, J., González-Pérez, M., de la Osa, M. C., Borobia, A. M., Castaño, L. A., Bertran, M. J., Campins, M., Portolés, A., Lora, D., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4066707
PERSISTENT IMMUNITY AFTER MILD SARS CoV-2 INFECTION - THE CoNAN-LONG TERM STUDY -Preprint
Schnizer, C., Andreas, N., Vivas, W., Kamradt, T., Baier, M., Kiehntopf, M., Glöckner, S., Scherag, A., Löffler, B., Kolanos, S., et al. (2022) · medRxiv · doi:10.1101/2022.07.05.22277237
Inflammatory environment in patients with COVID-19: Systematic review
Ventura, I. (2023) · Nereis Interdisciplinary Ibero-American Journal of Methods Modelling and Simulation · doi:10.46583/nereis_2022.1.1036
The impact of ENT manifestation in COVID-19 patients
Georgescu, B., Neagu, B., Osman, A., Mocanu, C. L., & Rugină, S. (2022) · Romanian Journal of Infectious Diseases · doi:10.37897/rjid.2022.3.4 · Cited by 1
Alali, A. M., Almakki, A., & Albadran, M. M. (2023) · Romanian Journal of Infectious Diseases · doi:10.37897/rjid.2023.2.2 · Cited by 1
Thole, L. M. L., Toth, L., Proß, V., Siegle, J., Stahl, C., Hermsdorf, G., Knabe, A., Winkler, A., Schrezenmeier, E. V., Ludwig, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1239519 · Cited by 1
“Spike-speci fi c CD4 + T cells were identi fi ed as depicted in Supplemental Figure 4A according to co-expression of CD137 and CD154 after peptide mix stimulation, as reported earlier (17 – 19).”
InfluentialSelf-citationImpaired homeostasis of T follicular helper cells in elderly patients with COVID-19Preprint
Wang, Y., Wang, Q., He, F., Qiao, N., Li, X., Wei, L., Sun, L., Dai, W., Li, Y., Pang, X., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3629075/v1
Starshinova, A. A., Kudryavtsev, I. V., Rubinstein, A., Михайловна, М. А., Ling, H., Zhuang, M., Starshinova, A. Y., Dovgaluk, I., & Kudlay, D. A. (2024) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-eou-16874 · Cited by 1
Identifying T-cell clubs by embracing the local harmony between TCR and gene expressions
Zou, Y., Luo, J., Chen, L., Wang, X., Liu, W., Wang, R. H., & Li, S. C. (2024) · Molecular Systems Biology · doi:10.1038/s44320-024-00070-5
“Certain V genes, including TRBV7-9, TRBV20-1, and TRBV27, were commonly used across different severity levels (Fig.”
InfluentialScaling, Power-Law First Return Times, and Non-Ergodicity
Lambert, D. R. (2022) · University of North Texas Digital Library (University of North Texas) · doi:10.12794/metadc1987323
Jia, Q., Bielefeldt‐Ohmann, H., Masleša-Galić, S., Bowen, R. A., & Horwitz, M. A. (2025) · Vaccines · doi:10.3390/vaccines13060633
“This aligns with studies showing the presence of M, N, and RdRp-specific T-cells correlate with milder disease, even in unvaccinated individuals exposed to β -hCoV [32,41,42].”
Effect of COVID-19 Infection on the Immune Response to the SARS-CoV-2 Vaccine in Rheumatoid Patients
Gallardo, M. J., Gómez, Y. M., Villar, J. D., & Zapata, F. (2025) · COVID · doi:10.3390/covid5100179
The role of innate immune cells in the pathogenesis of coronavirus infection caused by SARS-CoV-2
Mikhailov, A. O., Плехова, Н. Г., Toropkova, L. A., Анатольевна, С. С., & Belevich, I. O. (2025) · Acta medica Eurasica · doi:10.47026/2413-4864-2025-3-68-97 · Cited by 1
Valdez‐Cruz, N. A., García-Hernández, E., Espitia, C., Cobos-Marín, L., Altamirano, C., Bando-Campos, C. G., Cofas‐Vargas, L. F., Coronado-Aceves, E. W., González-Hernández, R. A., Hernández‐Peralta, P., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14471586
Plasencia-Rodríguez, C., Martínez‐Feito, A., Hernández, M., Molina, L. D. P., Novella-Navarro, M., Serrano, Y., González‐Muñoz, M., Peiteado, D., Bonilla, G., Monjo, I., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26611583
Leveraging SARS-CoV-2-induced pre-existing humoral and cellular immunity for tumor elimination
Chen, L., Yu, Q., Duan, S., Mao, Q., Han, Y., Tang, S., Yao, W., Gao, X., & Tian, H. W. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116114
Zapparoli, E., Lavezzo, E., Tonnelé, H., Simeoni, F., Guo, J., Walter, K., Tascini, A. S., Sharapov, S., Elyanow, R., Bado, M., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1718158
Summer, S., Wolf, H. M., Weber, V., & Fischer, M. B. (2026) · Cells · doi:10.3390/cells15070592
“…100 ng/mL LPS stimulation, a combination of LPS and SARS-CoV-2 peptides as well as treatment with the 100 µ M TLR4 inhibitor Tak 242 in combination with SARS-CoV-2 peptides for 24 h. Tak 242 inhibitor (resatorvid) downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF [54].”
InfluentialCrausaz, M. (2022) · theses.fr (ABES) · doi:10.70675/d0a5defazaeb0z46a2zb177z225779634e8f
Dal‐Pizzol, F., Caetano, R. D. C., Ribeiro, L. D. S., Matsunaga, N. Y., Dal-Pizzol, H. R., Escovar, L. R., PIZZOL, R. R. D., Prestes, G., Gelain, D. P., Moreira, J. C. F., et al. (2026) · Heart & Lung · doi:10.1016/j.hrtlng.2026.102897
Metadata
- Authors
- Sattler, A., Angermair, S., Stockmann, H., Heim, K. M., Khadzhynov, D., Treskatsch, S., Halleck, F., Kreis, M. E., & Kotsch, K.
- Corresponding author
- Sattler, Arne
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-11-03
- Volume
- 130
- Issue
- 12
- Pages
- 6477-6489
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7685725
- OpenAlex
- W3080524815
- Cited by
- 196
- References
- 55
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 14 · 2023: 25 · 2022: 52 · 2021: 80 · 2020: 10
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sonnenfeldstiftung (FACS facility support)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- SARS-CoV-2, COVID-19 pandemic, T cell response, CD4+ T helper cells, cell-mediated immunity, membrane proteins, nucleocapsid protein, spike protein, Th1 response, PD-1, interleukin-2, interferon-gamma, age, comorbidities, APACHE II score, mortality, intensive care, disease severity
- MeSH terms
- COVID-19, SARS-CoV-2, Adult, Age Factors, Aged, Aged, 80 and over, Disease Susceptibility, Female, Humans, Interferon-gamma, Interleukin-2, Male, Middle Aged, Severity of Illness Index, Th1 Cells, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.